{"title":"Big Pharma’s fight against drug price reforms takes weird, desperate turn","link":"https://arstechnica.com/?p=2034140","date":1719520142000,"content":"<div>\n<figure>\n  <img src=\"https://cdn.arstechnica.net/wp-content/uploads/2024/02/GettyImages-849503162-800x533.jpeg\" alt=\"Stephen Ubl, president and chief executive officer of Pharmaceutical Research and Manufacturers of America (PhRMA), speaks during a Bloomberg Live discussion in Washington, DC, in 2017. \" />\n      <p><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2024/02/GettyImages-849503162-scaled.jpeg\">Enlarge</a> <span>/</span> Stephen Ubl, president and chief executive officer of Pharmaceutical Research and Manufacturers of America (PhRMA), speaks during a Bloomberg Live discussion in Washington, DC, in 2017.  (credit: <a href=\"https://www.gettyimages.com/detail/news-photo/stephen-ubl-president-and-chief-executive-officer-of-news-photo/849503162?adppopup=true\">Getty | Andrew Harrer</a>)</p>  </figure>\n\n\n\n\n\n\n<div><a name=\"page-1\"></a></div>\n<p>After <a href=\"https://arstechnica.com/science/2024/02/judge-tosses-big-pharma-suit-claiming-drug-price-negotiation-is-unconstitutional/\">a series of decisive court losses</a>, the pharmaceutical industry appears to be taking its fight against Medicare drug price negotiations directly to the people—and the White House is not impressed.</p>\n<p>This week, the high-powered industry group PhRMA (the Pharmaceutical Research and Manufacturers of America) released two eye-catching attacks on federal efforts to lower America's singularly astronomical drug prices. In <a href=\"https://phrma.org/resource-center/Topics/Access-to-Medicines/New-Analysis-The-IRA-Could-Lead-to-Higher-Out-of-Pocket-Costs-for-3-point-5-Million-Medicare-Patients\">a press release Tuesday</a>, PhRMA announced an analysis suggesting that the Medicare drug price negotiations—part of the Biden administration's 2022 Inflation Reduction Act—could actually cost some seniors and people with disabilities slightly more in out-of-pocket costs. <a href=\"https://www.milliman.com/en/insight/ira-mdpnp-impact-on-beneficiary-oop\">The analysis</a>, however, relies on a key—and questionable—assumption that the federal government will set price limits using the highest possible estimate for maximum fair prices in 2026.</p>\n<p>Milliman, the consulting firm PhRMA commissioned to do the study, cautioned that the actual prices \"will certainly vary due to differences in unit cost and utilization trend, 2026 benefit designs, and actual 2026 maximum fair prices.\"</p></div><p><a href=\"https://arstechnica.com/?p=2034140#p3\">Read 7 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=2034140&amp;comments=1\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"68f8309619a7e6645362eab8c0aeee66b9fe3055306974d97c1baf0446513ed1","category":"Tech"}